HomeQuestion

Would you consider neoadjuvant immunotherapy in a patient with Lynch syndrome and urothelial cancer?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Are there scenarios where you would still prefer adjuvant nivolumab based on known pathologic risk over using perioperative durvalumab for patients with muscle invasive bladder cancer?

How do you interpret NIAGARA efficacy given that adjuvant nivolumab was not administered in the comparator arm?

Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?

In patients with muscle-invasive bladder cancer seeking bladder preservation, would positive ctDNA affect your approach to trimodality therapy?

Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.